Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

00 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRME
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... GUELPH, ON , April 16, 2015 /CNW/ - Bioenterprise ... opening its newest office in Charlottetown ... with the Prince Edward Island ADAPT Council for the ... are looking forward to working with PEI ADAPT.  They ... Maritimes for more than a decade," explains Dave ...
(Date:4/16/2015)... 16, 2015 A new infographic compiles ... for research institutions to learn how Apple’s new framework ... The timing is ideal since Apple made Research ... is an open-source framework for developing medical research apps ... way for researchers to collect secure clinical data and ...
(Date:4/16/2015)... , April 16, 2015  Scientists from Cleave Biosciences ... on the Horizon," at the American Association for Cancer ... on Sunday, April 19, 2015 from 3:15pm ... Director of Biology, will present new in vivo and ... oral inhibitor of p97, a critical enzyme that controls ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono ... KGaA, Darmstadt, Germany , appointed ... President, Head of Global Clinical Development.  Dr. Reicin ... including experience in Oncology and Immunology. She is ... having served as a Vice President in various ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3
... 5 Experts from PAREXEL International Corporation (Nasdaq: ... services provider, will address important industry issues at ... being held from March 23 - 25, 2009 ... leaders will present on topics ranging from global ...
... BEACH, California and AMSTERDAM, March 5 ,Agendia, a ... the,appointment of Dr. Albert A. (Al) Luderer to ... Dr. Luderer has more than 30 years of ... therapeutic development. Currently, he,is the Chief Executive Officer ...
... WALTHAM, Mass., March 5 Proteon Therapeutics, Inc., announced ... Series B equity financing, led by MPM Capital on ... L.P. This announcement follows the initiation of a ... PRT-201, in patients with end stage renal disease undergoing ...
Cached Biology Technology:PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 2PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 3PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 4PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 5Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board 2Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Lugano, Switzerland, 14 September 2012 -- Ahead of the ... be released during the ESMO 2012 Congress, over 1,600 ... 2012 at 9:00 (CEST) to anticipate the flavor of ... emerging strategies set to combat cancer, signposting future directions ...
... have developed a method that for the first time ... proteins and subsequently remove them in a repeatable cycle., ... this week in the journal Nature Methods , ... naturally formed proteins in order to create better antibiotics, ...
... ,Boston (Sept. 14, 2012) Eye injuries in ... as weapons, tactics, technology and strategies have evolved. ... cause extensive damage areas not protected by body armor. ... Institute, Massachusetts Eye and Ear will convene in Boston, ...
Cached Biology News:Noteworthy studies at the ESMO 2012 Congress 2Noteworthy studies at the ESMO 2012 Congress 3Noteworthy studies at the ESMO 2012 Congress 4Noteworthy studies at the ESMO 2012 Congress 5Noteworthy studies at the ESMO 2012 Congress 6Noteworthy studies at the ESMO 2012 Congress 7Chemists develop reversible method of tagging proteins 2Chemists develop reversible method of tagging proteins 3
HLA-DRbeta (DA2)...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
... antiserum This NPY Y2 antibody has ... is currently being characerized in brain. The antibody ... and appears to work better on mose tissue, ... full characterizarion in dorsal root ganglion and spinal ...
... This adapter allows ... (AB-0800 and AB-1000) PCR ... in the ABI PRISM® ... contact ABgene® for information ...
Biology Products: